Relationship between prognosis and glucose transporter-1 and Ki-67 expression in obstructive colon cancer pre and post stent placement

Table 1 Relationship between glucose transporter-1 expression and various patient characteristics (n = 71), n (%)

Clinicopathologic parameters	Total cases (%)	GLUT-1 (pre-SEMS)			GLUT-1 (post-SEMS)
		High (%)	Low (%)	P value	High (%)	Low (%)	P value
	71 (100)	10 (14.1)	61 (85.9)		31 (43.7)	40 (56.3)
Age
< 65	31 (43.7)	6 (60.0)	25 (41.0)	0.435	17 (54.8)	14 (35.0)	0.095
≥ 65	40 (56.3)	4 (40.0)	36 (59.0)		14 (45.2)	26 (65.0)
Sex
Female	28 (39.4)	3 (30.0)	25 (41.0)	0.757	11 (35.5)	17 (42.5)	0.549
Male	43 (60.6)	7 (70.0)	36 (59.0)		20 (64.5)	23 (57.5)
Location
Sigmoid	48 (67.6)	8 (80.0)	40 (65.6)	0.590	20 (64.5)	28 (70.0)	0.624
Transverse to descending	23 (32.4)	2 (20.0)	21 (34.4)		11 (35.5)	12 (30.0)
Differentiation
Well and moderately	68 (95.8)	10 (100.0)	58 (95.1)	0.630	31 (100.0)	37 (92.5)	0.335
Poorly	3 (4.2)	0 (0)	3 (4.9)		0 (0)	3 (7.5)
Lymphovascular invasion
Absence	51 (71.8)	5 (50.0)	46 (75.4)	0.202	17 (54.8)	34 (85.0)	0.003a
Presence	20 (28.2)	5 (50.0)	15 (24.6)		14 (45.2)	6 (15.0)
Perineural invasion
Absence	48 (67.6)	4 (40.0)	44 (72.1)	0.099	19 (61.3)	29 (72.5)	0.317
Presence	23 (32.4)	6 (60.0)	17 (27.9)		12 (38.7)	11 (27.5)
pT stage
T3	14 (19.7)	3 (30.0)	11 (18.0)	0.651	3 (9.7)	11 (27.5)	0.061
T4	57 (80.3)	7 (70.0)	50 (82.0)		28 (90.3)	29 (72.5)
pN stage
Absence	25 (35.2)	3 (30.0)	22 (36.1)	0.988	8 (25.8)	17 (42.5)	0.144
Presence	46 (64.8)	7 (760.0)	39 (63.9)		23 (74.2)	23 (57.5)
pTNM stage
Ⅱ	25 (35.2)	3 (30.0)	22 (36.1)	0.988	8 (25.8)	17 (42.5)	0.144
Ⅲ	46 (64.8)	7 (70.0)	39 (63.9)		23 (74.2)	23 (57.5)
Ki67 (pre-SEMS)
High	45 (63.4)	8 (80.0)	37 (60.7)	0.101	20 (64.5)	25 (62.5)	0.861
Low	26 (36.6)	2 (20.0)	24 (29.3)		11 (35.5)	15 (37.5)
Ki67 (post-SEMS)
High	47 (66.2)	8 (80.0)	39 (63.9)	0.562	21 (67.7)	26 (65.0)	0.809
Low	24 (33.8)	2 (20.0)	22 (36.1)		10 (32.3)	14 (35.0)
Interval time
< 3 weeks	60 (84.5)	7 (11.7)	53 (88.3)	0.370	27 (45.0)	33 (54.5)	0.841
≥ 3 weeks	11 (15.5)	3 (27.3)	8 (72.3)		4 (36.4)	7 (63.6)

^aP < 0.05.

Ki67: High (expression level ≥ 30%) vs low (expression level < 30%); GLUT-1: High (scores of 3) vs Low (scores of 0-2). GLUT-1: Glucose transporter-1; SEMS: Self-expandable metallic stent.

Table 2 Univariate and multivariate analysis of cliniopathologic parameters on 3-year recurrence-free interval

Parameters	3-year recurrence-free interval
	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Age (≥ 65 vs < 65)	1.544	0.679-3.553	0.297
Sex (female vs male)	0.476	0.189-1.200	0.115
Location (sigmoid vs transverse to descending)	0.589	0.234-1.487	0.263
Differentiation (well and moderately vs poorly)	0.046	0-208.005	0.474
Lymphovascular invasion (absence vs presence)	3.352	1.497-7.508	0.030a	0.570	0.130-2.495	0.455
Perineural invasion (absence vs presence)	2.600	1.164-5.809	0.020a	1.963	0.500-7.698	0.334
pT stage (T3 vs T4)	30.671	0.540-1742.052	0.097
pN stage (absence vs presence)	4.841	1.442-16.247	0.011a	3.876	1.018-14.684	0.047a
pTNM stage (Ⅱ vs Ⅲ)	4.841	1.442-16.247	0.011a
Ki67 (pre-SEMS) (high vs low)	0.496	0.222-1.106	0.087
Ki67 (post-SEMS) (high vs low)	0.752	0.329-1.720	0.500
GLUT1 (pre-SEMS) (high vs low)	2.710	1.067-6.885	0.036a	3.490	1.165-10.453	0.026a
GLUT1 (post-SEMS) (high vs low)	4.317	1.709-10.904	0.002a	4.335	1.539-12.214	0.006a
Duration of CAPOX (3 months vs 6 months)	1.442	0.640-3.250	0.377

^aP < 0.05.

Ki67: High (expression level ≥ 30%) vs low (expression level < 30%); GLUT-1: High (scores of 3) vs low (scores of 0-2). GLUT-1: Glucose transporter-1; SEMS: Self-expanding metallic stent.